Alk-Abello AS (LTS:0OIR) FFO


LTS:0OIR Alk-Abello AS LTS:0OIR
90 GF Score
Price kr149.45
GF Value kr121.45
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Alk-Abello AS FFO?

FFO (Funds from operations) only applies to REITs.

LTS:0OIR
90GF Score
Alk-Abello AS LTS:0OIR
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Alk-Abello AS (LTS:0OIR) Overvalued in 2026?

Based on GuruFocus' analysis, Alk-Abello AS stock appears to be overvalued. The current stock price of kr149.45 is trading 23.1% above its estimated GF Value™ of kr121.45. GuruFocus considers Alk-Abello AS to be Modestly Overvalued.

Key valuation signals for LTS:0OIR:

  • FFO:
  • GF Value™: kr121.45 vs. price of kr149.45 (23.1% above fair value)
  • GF Score™: 90/100 with 5 warning signs

No single metric tells the full story. See the LTS:0OIR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Alk-Abello AS Business Description

Address Boge Alle 6-8, Horsholm, DNK, DK-2970
Alk-Abello AS is a biotechnology company that focuses on pharmaceutical prevention, diagnosis, and treatment of allergies. The company is focused on respiratory diseases, including allergic rhinitis and allergic asthma. Moreover, the firm specializes in venom immunotherapy for patients suffering from bee and wasp allergies. The company's treatments induce a protective immune response that provides sustained symptom relief. Its primary focus is on allergy patients whose disease is not well controlled, despite the use of symptom-relieving medication. The company operates in Europe, North America and International Markets. It derives maximum revenue from Europe.
90GF Score

Get the complete analysis for LTS:0OIR

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr149.45
Price
kr121.45
GF Value